{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Will be compared as difference in proportions with 95% confidence intervals.","groups":[{"description":"Patients receive placebo PO twice daily in week 1 and then once daily in weeks 2-11. Patients also receive cisplatin IV over 3 hours once in weeks 2, 5, and 8 and undergo radiotherapy 5 days a week in weeks 2-8.\n\nplacebo: Given PO\n\ncisplatin: Given IV\n\nradiation therapy: Undergo radiotherapy\n\nquality-of-life assessment: Ancillary studies","id":"OG000","title":"Arm I (Placebo, Cisplatin, and Radiotherapy)"},{"description":"Patients receive selenomethionine PO twice daily in week 1 and then once daily in weeks 2-11. Patients also receive cisplatin and undergo radiotherapy as in arm I.\n\nselenomethionine: Given PO\n\ncisplatin: Given IV\n\nradiation therapy: Undergo radiotherapy\n\nquality-of-life assessment: Ancillary studies","id":"OG001","title":"Arm II (Selenomethionine, Cisplatin, and Radiotherapy)"}],"paramType":"NUMBER","populationDescription":"All treated and eligible patients","reportingStatus":"POSTED","timeFrame":"Up to 5 years post-treatment","title":"Incidence of Grade 3 or 4 Treatment-related Toxicities, Including Xerostomia","type":"SECONDARY","unitOfMeasure":"number of xerostomia events"}